Anygen Co., Ltd. (KOSDAQ: 196300)

Market Cap	76.84B
Revenue (ttm)	6.12B
Net Income (ttm)	-8.67B
Shares Out	6.00M
EPS (ttm)	-1,452.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,214
Open	13,450
Previous Close	13,450
Day's Range	12,570 - 14,500
52-Week Range	9,000 - 19,000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Anygen

Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-331 targeted for anti-cancer therapy, currently under pre-clinical development phase; AGM-130 indicated for the treatment of triple negative breast cancer, currently under Phase I development phase; AGM-380 indicated for the treatment of viral infection, currently ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196300

Financial Performance

In 2023, Anygen's revenue was 5.61 billion, a decrease of -35.23% compared to the previous year's 8.66 billion. Losses were -9.08 billion, 46.3% more than in 2022.